NASDAQ : LYEL
Lyell Immunopharma, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 10.83 USD (Oct 30, 2026, 2:17 PM EDT) · Market cap 265.39M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 266.62M |
| Enterprise Value | 85.22M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 24.51M |
| Shares Outstanding | 24.51M |
| Shares Change (YoY) | +49.16% |
| Shares Change (QoQ) | +6.80% |
| Owned by Insiders (%) | 7.26% |
| Owned by Institutions (%) | 36.59% |
| Float | 12.13M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 9,874.66 |
| Forward PS | 16,694.80 |
| PB Ratio | 1.09 |
| P/TBV Ratio | 1.14 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 3,156.15 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 5.36 |
| Quick Ratio | 5.12 |
| Debt / Equity | 0.20 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -93.28% |
| Return on Assets (ROA) | -34.18% |
| Return on Invested Capital (ROIC) | -37.53% |
| Return on Capital Employed (ROCE) | -70.21% |
| Weighted Average Cost of Capital (WACC) | 3.46% |
| Revenue Per Employee | $168 |
| Profits Per Employee | -$1.54M |
| Employee Count | 161 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | -0.03 |
| 52-Week Price Change | -34.69% |
| 50-Day Moving Average | 10.93 |
| 200-Day Moving Average | 16.81 |
| Relative Strength Index (RSI) | 59.44 |
| Average Volume (20 Days) | 162,106 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 1.40M |
| Short Previous Month | 1.26M |
| Short % of Shares Out | 5.71% |
| Short % of Float | 11.52% |
| Short Ratio (days to cover) | 7.91 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 27,000 |
| Gross Profit | 27,000 |
| Operating Income | -190.46M |
| Pretax Income | -248.48M |
| Net Income | -248.48M |
| EBITDA | -180.94M |
| EBIT | -190.46M |
| Loss Per Share | -$11.82 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 204.10M |
| Total Debt | 46.60M |
| Net Cash | 181.40M |
| Net Cash Per Share | $7.40 |
| Equity (Book Value) | 233.82M |
| Book Value Per Share | 9.99 |
| Working Capital | 173.67M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -133.26M |
| Capital Expenditures | -711,000 |
| Depreciation & Amortization | 9.52M |
| Net Borrowing | n/a |
| Free Cash Flow | -133.97M |
| FCF Per Share | -$5.47 |
Margins
| Measure | Value |
|---|
| Gross Margin | 100.00% |
| Operating Margin | -705,411.11% |
| Pretax Margin | -920,285.19% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -49.16% |
| Shareholder Yield | -49.16% |
| Earnings Yield | -108.66% |
| FCF Yield | -50.25% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $37.88 |
| Price Target Difference | 248.16% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | 943.37% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jun 2, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -5.88 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |